6 research outputs found
Η μελέτη του συνεργατικού ρόλου της σιωπηρής ισχαιμίας στην εμφάνιση κοιλιακών αρρυθμιών σε στεφανιαίους ασθενείς
No full textunavailabl
US outward foreign direct investment in the European Union and the implementation of the single market: empirical evidence from a cohesive framework
No full textIn this article we investigate the determinants of US outward Foreign Direct Investment (FDI) in the European Union for the period 1982-2002. The data set allowed us to discern differences in the pattern of US FDI between EU core and EU periphery countries, as well as over different time periods during the last two decades. The results indicate that the US FDI pattern varies among different groups of countries and that there was a restructuring in multinational firms' investment activity after the implementation of the single market plan. Agglomeration factors, market size, qualified and productive labour and cost efficiency of local production seem to dominate in the location choice of US investors. Copyright (c) 2008 The Author(s). Journal compilation (c) 2008 Blackwell Publishing Ltd.
European Union Foreign Direct Investment in China: Evidence from a Panel Study of EU Manufacturing Firms, 1998-2007
No full textThe paper examines determinants of the EU‘s FDI into the China by using a newly available Manufacturing firm-level data set for the period 1998-2007 from the State Statistical Bureau of China. The theoretical framework of the paper builds on Dunning's ownership–location–internalization (OLI) paradigm, incorporating the institutional determinants to test international production by EU firms in emerging market. The paper analyses recent trends and patterns of EU FDI and its firms‘ characteristics in China. This study applies both static and dynamic panel data approaches (fixed effects and GMM system estimators) to test the presence of agglomeration effect of past FDI. It finds that EU FDI in China is positively associated with export intensity and labour cost. However, technology and profitability of the firm show unexpected results, not lining with theory in the study. The results further suggest that locational factors with regard to macroeconomic and legal environment are also considered by EU firms when deciding on FDI in China. The findings have important implications for practitioners and policymaking
an e-Delphi consensus study
No full textUPDATE NOTICE: Correction: Moving towards a core measures set for patient safety in perioperative care: an e-Delphi consensus study (PLoS One. 2024;19(10):e0311896). PLoS One. 2025;20(1):e0317063. Doi: 10.1371/journal.pone.0317063. Funding Information: The work underlying this manuscript is encompassed in the European project SAFEST (Improving quality and patient SAFEty in surgical care through STandardisation and harmonisation of perioperative care in Europe). This project receives funding from the European Union\u2019s Horizon Europe research and innovation programme under grant agreement No 101057825. Link: https://cordis.europa.eu/project/ id/101057825 The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors would like to commend the SAFEST consortium members for their contribution: Daniel Arnal-Velasco, Joaquim Baneres, Ashish Bartakke, Hiske Calsbeek, Genis Carrasco, Pedro Casaca-Carvalho, Edoardo De Robertis, Yvette Emond, Neus Fabregas, Javier Garc\u00EDa-Silva, Pascal Garel, Oliver Groene, Anita Heideveld-Chevalking, Mari Kangasniemi, Janne Kommusaar, Kaja Kristensen, Andreia Leite, Irene Leon, Ismael Mart\u00EDnez-Nicol\u00E1s, David Marx, Marie Nabbe, Ana Beatriz Nunes, Carola Orrego, Kaja Polluste, Janne P\u00FChvel, Eva Romero-Garcia, Yolanda Sanduende-Otero, Willemijn Sch\u00E4fer, Caroline Schlinkert, Ayshe Seyfulayeva, Victor Soria-Aledo, Paulo Sousa, Joel Starkopf, Rosa Sunol, Helena Vall, Claudia Valli, Nina van der Schoot, Lilian Van Tuyl, Frantisek Vlcek, Marieke Voshaar, Cordula Wagner, Sophie Wang, Adam \u017Daludek, and Sandro Zamarian. The authors would also like to acknowledge the SAFEST Scientific Advisory Group members for contributing to this study: Aamer Ahmed, Fragkiskos Angelis, Catarina Baptista, Metaxia Bareka, Kateryna Bielka, Mercedes Bilbao, Federico Bilotta, Elvira Bisbe, Dialina Brilhante, Pedro Carrascal, Pedro Delgado, Zsuzsanna Farkas-Pall, Loredana Gigli, Helen Haskell, Arvid Steinar Haugen, Jan Hofland, Beverley Hunt, Ib Jammer, Janek Kapper, Natasa Kovac, Susana Lorenzo, Rui Malheiro, Xose Manuel Meijome, Jannicke Mellin-Olsen, Margaret Murphy, Maria Ntalouka, Marta Dora Ornelas, Margarita Ovsepyan, Maria Papadakaki, Danica Rotar Pavlic, Julien Picard, Marek Pietruszka, Benedikt Preckel, Finn Radktke, Jos\u00E9 Manuel Rodr\u00EDguez, Narimantas Evaldas Samalavicius, Pedro Vieira dos Santos, Ed Schoemaker, Kawaldip Sehmi, Henri\u00EBtte Smid-Nanninga, Joel Starkopf, John Tansley, Francesco Venneri, Matthias Weigl, and Argyro Zoumprouli. Publisher Copyright: Copyright: © 2024 Dinis-Teixeira et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.A Core Measures Set (CMS) is an agreed standardized group of measures that should be assessed and reported in research for a specific condition or clinical area. This study undertook the development of a CMS for Patient Safety through a two-round, web-based Delphi consensus approach, in the context of the “Improving quality and patient SAFEty in surgical care through STandardisation and harmonization of perioperative care in Europe” (SAFEST) project—a collaborative, patient-centered and evidence-based European Union-funded project that aims to generate action-oriented evidence in perioperative care. We developed an Initial List of Measures via an umbrella review following the deployment of an e-Delphi method with an inclusive panel of experts to prioritize measures towards a consensualized Final List of Measures. All measures were rigorously assessed for both importance and feasibility. After the two rounds of the e-Delphi consensus method we observed 13 preoperative measures (40.6% of the initial number), 24 intraoperative measures (66.7%), 25 postoperative measures (20.3%) and 23 mixed period measures (41.1%) met consensus criteria for both importance and feasibility. Higher scores were detected in importance ratings compared to feasibility across all groups of measures. Importantly, numeric averages regarding pain-related measures differed in the assessment of patients when compared to that of Healthcare Professionals (HCPs). This work not only informs future SAFEST iterations but also sets a precedent for research into valid, patient-centered, and action-oriented perioperative safety measures.publishersversionpublishersversionpublishe
Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure
No full textBACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.)
Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure
No full textBackground:
The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown.
Methods:
We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes.
Results:
During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P=0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro–B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups.
Conclusions:
Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329. opens in new tab; EudraCT number, 2016-002299-28. opens in new tab.
